|Ms. Carol Pan||Principal Financial Officer, Principal Accounting Officer and Treasurer||60k||N/A||1984|
|Mr. Jeffrey Robinson||Chairman & CEO||N/A||N/A||N/A|
|Dr. Hyder Ali Khoja||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Anna Leralta Morera||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Luka Marjanovic||Head of Product Devel. for the MJ MedTech in South Africa||N/A||N/A||N/A|
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Barcelona, Spain.
Wuhan General Group (China), Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.